Generic placeholder image

Anti-Cancer Agents in Medicinal Chemistry

Editor-in-Chief

ISSN (Print): 1871-5206
ISSN (Online): 1875-5992

Biography

Meet the Editorial Board Member

Author(s): Ana Conejo-García

Volume 23, Issue 7, 2023

Published on: 09 February, 2023

Page: [735 - 735] Pages: 1

DOI: 10.2174/187152062307230209100951

Next »
[1]
Espejo-Román, J.M.; Rubio-Ruiz, B.; Cano-Cortés, V.; Cruz-López, O.; Gonzalez-Resines, S.; Domene, C.; Conejo-García, A.; Sánchez-Martín, R.M. Selective anticancer therapy based on a HA-CD44 interaction inhibitor loaded on polymeric nanoparticles. Pharmaceutics, 2022, 14(4), 788.
[http://dx.doi.org/10.3390/pharmaceutics14040788]
[2]
Cruz-López, O.; Ner, M.; Nerín-Fonz, F.; Jiménez-Martínez, Y.; Araripe, D.; Marchal, J.A.; Boulaiz, H.; Gutiérrez-de-Terán, H.; Campos, J.M.; Conejo-García, A. Design, synthesis, HER2 inhibition and anticancer evaluation of new substituted 1,5-dihydro-4,1-benzoxazepines. J. Enzyme Inhib. Med. Chem., 2021, 36(1), 1553-1563.
[http://dx.doi.org/10.1080/14756366.2021.1948841]
[3]
Rubio-Ruiz, B.; Serrán-Aguilera, L.; Hurtado-Guerrero, R.; Conejo-García, A. Recent advances in the design of choline kinase α inhibitors and the molecular basis of their inhibition. Med. Res. Rev., 2020, 41(2), 902-927.
[http://dx.doi.org/10.1002/med.21746]
[4]
Brancucci, N.M.B.; Gerdt, J.P.; Wang, C.; De, N.M.; Philip, N.; Adapa, S.R.; Zhang, M.; Hitz, E.; Niederwieser, I.; Boltryk, S.D.; Laffitte, M.C.; Clark, M.A.; Grüring, C.; Ravel, D.; Blancke, S.A.; Demas, A.; Bopp, S.; Rubio-Ruiz, B.; Conejo-Garcia, A.; Wirth, D.F.; Gendaszewska-Darmach, E.; Duraisingh, M.T.; Adams, J.H.; Voss, T.S.; Waters, A.P.; Jiang, R.H.Y.; Clardy, J.; Marti, M. Lysophosphatidylcholine regulates sexual stage differentiation in the human malaria parasite plasmodium falciparum. Cell, 2017, 171(7), 1544, e15.
[http://dx.doi.org/10.1016/j.cell.2017.10.020]
[5]
Cruz-López, O.; Ramírez, A.; Navarro, S.A.; García, M.A.; Marchal, J.M.; Campos, J.M.; Conejo-García, A. 1-(Benzenesulfonyl)-1,5-dihydro-4,1-benzoxazepine as a new scaffold for the design of antitumor compounds. Future Med. Chem., 2017, 9(11), 1129-1140.
[6]
Serrán-Aguilera, L.; Denton, H.; Rubio-Ruiz, B.; López-Gutiérrez, B.; Entrena, A.; Izquierdo, L.; Smith, T.K.; Conejo-García, A.; Hurtado-Guerrero, R. Plasmodium falciparum choline kinase inhibition leads to a major decrease in phosphatidylethanolamine causing parasite death. Sci. Rep., 2016, 12(6), 33189.
[http://dx.doi.org/10.1038/srep33189]
[7]
Ramírez, A.; Boulaiz, H.; Morata-Tarifa, C.; Perán, M.; Jiménez, G.; Picon-Ruiz, M.; Agil, A.; Cruz-López, O.; Conejo-García, A.; Campos, J.M.; Sánchez, A.; García, M.A.; Marchal, J.A. HER2-signaling pathway, JNK and ERKs kinases, and cancer stem-like cells are targets of Bozepinib. Oncotarget, 2014, 5(11), 3590-3606.
[http://dx.doi.org/10.18632/oncotarget.1962]
[8]
Rubio-Ruiz, B.; Figuerola-Conchas, A.; Ramos-Torrecillas, J.; Capitán-Cañadas, F.; Ríos-Marco, P.; Carrasco, M.P.; Gallo, M.Á.; Espinosa, A.; Marco, C.; Ruiz, C.; Entrena, A.; Hurtado-Guerrero, R.; Conejo-García, A. Discovery of a new binding site on human choline kinase α1: design, synthesis, crystallographic studies, and biological evaluation of asymmetrical bispyridinium derivatives. J. Med. Chem., 2014, 57(2), 507-515.
[http://dx.doi.org/10.1021/jm401665x]
[9]
Rubio-Ruiz, B.; Castillo-Acosta, V.M.; Pérez-Moreno, G.; Espinosa, A.; González-Pacanowska, D.; Ruiz-Pérez, L.M.; Entrena, A.; Conejo-García, A. In vitro antiplasmodial and cytotoxic activities of asymmetrical pyridinium derivatives. Eur. J. Med. Chem., 2014, 85, 289-292.
[http://dx.doi.org/10.1016/j.ejmech.2014.07.105]
[10]
Sahún-Roncero, M.; Rubio-Ruiz, B.; Saladino, G.; Conejo-García, A.; Espinosa, A.; Velázquez-Campoy, A.; Gervasio, F.L.; Entrena, A.; Hurtado-Guerrero, R. The mechanism of allosteric coupling in choline kinase α1 revealed by the action of a rationally designed inhibitor. Angew. Chem. Int. Ed. Engl., 2013, 52(17), 4582-4586.
[http://dx.doi.org/10.1002/anie.201209660]

© 2024 Bentham Science Publishers | Privacy Policy